HEMABATE SOLUTION

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

CARBOPROST (CARBOPROST TROMETHAMINE)

Commercializzato da:

PFIZER CANADA ULC

Codice ATC:

G02AD04

INN (Nome Internazionale):

CARBOPROST

Dosaggio:

250MCG

Forma farmaceutica:

SOLUTION

Composizione:

CARBOPROST (CARBOPROST TROMETHAMINE) 250MCG

Via di somministrazione:

INTRAMUSCULAR

Confezione:

1ML

Tipo di ricetta:

Prescription

Area terapeutica:

OXYTOCICS

Dettagli prodotto:

Active ingredient group (AIG) number: 0133100001; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2003-09-16

Scheda tecnica

_ _
PRODUCT MONOGRAPH
HEMABATE
® STERILE SOLUTION
(carboprost tromethamine injection USP)
250 µg/mL
PROSTAGLANDIN
Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
DATE OF REVISION:
FEBRUARY 21, 2014
CONTROL NO. 170114
®
Pfizer Enterprises SARL
Pfizer Canada Inc, Licensee
Pfizer Canada Inc. 2014
_` _
_HEMABATE (carboprost tromethamine) Product Monograph _
_Page 2 of 23 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY OF PRODUCT INFORMATION
..................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................10
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
................................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
DETAILED PHARMACOLOGY
...................................................................................